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Abstract 
Our previous tudy on chimeric mutants of a-galactosidase uggested that two peptide regions encoded by exons 1-2 and 6 of the 
enzyme gene contribute to substrate recognition (Ishii, S. et al. (1994) Biochim. Biophys. Acta 1204, 265-270). In this study, we 
constructed five single amino acid substitutions for functional analysis of the amino acid residues around glutamine-279, the mutation site 
detected in an atypical Fabry disease patient. Two mutants, Q280S (Gln280---, Ser; CAA---, TCA) and T282A (Thr282--, Aia; 
ACT ---, GCT), showed increased K m and decreased thermostability as compared with normal enzyme. Circular dichroism spectrum was 
not modified. An additional chimeric mutation in the exon 1-2 region by substitution with the homologous sequence of a-N-acetylgalac- 
tosaminidase cDNA restored catalytic activity and thermostability n both mutants. These data indicated the functional significance of 
glutamine-280 and threonine-282 for expressing the activity and stability of a-galactosidase molecule, and also the presence of an 
intramolecular interaction between the two peptide regions encoded by exons 1-2 and 6. 
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I. Introduction 
Human a-galactosidase (a-GaD is a lysosomal hydro- 
lase responsible for the catabolism of glycoconjugates with 
terminal a-galactosidic moiety [1]. The accumulation of 
glycosphingolipids, mainly globotriaosylceramide, has been 
observed in tissues from patients with Fabry disease, an 
X-linked recessive disorder caused by a deficiency of this 
enzyme. The gene structure for a-Gal has been reported 
[2-4], but the functional structure of the enzyme protein is 
poorly understood. 
The mutations in classic Fabry disease have been de- 
tected in highly scattered regions of the ot-Gal gene [5-14], 
but the four mutations for a late-onset atypical variant of 
this disease are single base substitutions localized in the 
upstream region of exon 6 (Q279E, M296V, and R301Q) 
or at a glycosylation site (N215S) [14]. Recently, we 
characterized a gene expression product for one of them, 
Q279E, and suggested that the mutation site is closely 
associated with the galactose recognition site [15]. 
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Another approach to the active site of a-Gal using 
chimeric mutants howed a functional significance of the 
region around glutamine-279. In a previous tudy [16], we 
constructed three mutants of a-Gal by chimeric substitu- 
tion with the corresponding sequences of a-N-acetylga- 
lactosaminidase (a-NAGA), which has a high amino acid 
sequence homology (47%) with that of c~-Gal [17,18]. One 
of the chimeric mutants CMB6, comprising the #245-272 
a-NAGA sequence (corresponding to the #259-286 a-Gal 
sequence), acquired an increase in K m and a decrease in 
specific activity. 
The purpose of the present study was to identify the 
amino acid residues responsible for the a-Gal activity in 
the region around the amino acid glutamine-279. 
2. Materials and methods 
2.1. Mutagenesis and subcloning 
Seven amino acid substitutions had been introduced 
simultaneously in the CMB6 mutation described in our 
previous tudy [16] (Fig. 1). In this study, we prepared five 
individual amino acid substitutions instead, around one 
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mutation site in the exon 6 region, which had been de- 
tected in an atypical Fabry patient. Base substitutions were 
introduced with an oligonucleotide-directed in vitro muta- 
genesis kit (Amersham, Buckinghamshire, UK): W277L 
(Trp277 ~ Leu; TGG ~ TI'G), N278E (Asn278 ~ Gin; 
AAT ~ GAG), Q280S (Gln280 ~ Ser; CAA ~ TCA), 
V281R (Va1281 ---> Arg; GTA ~ CGA) and T282A 
(Thr282 ---> Ala; ACT ~ GCT). The primers were 5'-GC- 
CTCAGCTTGAATCAGCA-3', 5'-CTCAGCTGGGAG- 
CAGCAAGT-3', 5'-TGGAATCAGTCAGTAACTCAG-3', 
5 ' -AATCAGCAACGAACTCAGAT-3 ' ,  and 5'- 
CAGCAAGTAGCTCAGATGG-3', respectively. The 
replicative form DNA of the mutant M13 vector was 
isolated and digested with BgllI and KpnI. The resulting 
490-bp fragment was purified and inserted into the pA- 
cYM1 expression vector, containing a-Gal cDNA 
(pAcGal) [16] in place of the corresponding fragment. 
In some experiments, the chimeric substitution CMB12 
was added to the Q280S and T282A mutants (CMB12- 
Q280S and CMB12-T282A), with the BgllI-KpnI frag- 
ment in the pAcYM1 expression vector, containing 
chimeric mutant cDNA (pAcCMB12) [16]. The nucleotide 
sequence was confirmed by the dideoxy method using a 
7-DEAZA sequencing kit (Takara Shuzo, Kyoto, Japan). 
2.2. Expression and purification of mutant enzymes 
A recombinant baculovirus was prepared by simultane- 
ous transfection of Sf9 cells with pAcGal comprising the 
mutant DNA sequence and wild-type virus DNA (AcNPV). 
The recombinant virus with the mutant a-Gal sequence 
was selected from the culture medium by the limiting 
dilution method. Subsequently, Sf9 cells were infected 
with the recombinant virus for 18 h, and cultured in the 
serum-free Grace's medium for 6 days. The expressed 
mutant enzyme was collected from the culture medium, 
and purified by concanavalin A-Sepharose and Mono Q 
(Pharmacia LKB Biotechnology, Uppsala, Sweden) col- 
umn chromatography as described previously [16]. 
2.3. Enzyme assay and protein determination 
a-Gal activity was assayed with an artificial substrate, 
4MU-a-Gal (Nacalai Tasque, Kyoto, Japan) [19]. The 
reaction mixture, containing 5.0 mM 4MU-a-Gal in 0.1 M 
sodium citrate buffer (pH 4.6) was incubated at 37 ° C for 6 
min. The reaction was terminated with an excess amount 
of 0.1 M glycine buffer (pH 10.7). Protein concentration 
was monitored by 280 nm absorbance, with the extinction 
coefficient calculated for the a-Gal expressed in insect 
cells as described previously [16]. 
2.4. Characterization of mutant enzyme 
The circular dichroism (CD) spectrum was obtained 
with the Jasco J-600 spectropolarimeter (Japan Spectro- 
scopic, Tokyo, Japan). Each sample was suspended in 10 
mM sodium acetate buffer (pH 5.0), and the enzyme 
protein concentration was adjusted to 60/zg/ml.  
SDS-polyacrylamide g l electrophoresis was performed 
by the method of Laemmli [20]. The molecular weight of 
the native form protein was estimated according to the 
method of Andrews [21] by gel filtration on a column of 
Superose 12 (Pharmacia LKB Biotechnology) equilibrated 
with 25 mM 2-(N-morpholino)ethanesulfonic acid 
(MES)-NaOH buffer (pH 6.0), containing 0.1 M NaCl. 
Molecular weight markers for gel filtration were: aldolase 
(160 kDa), bovine serum albumin (67 kDa), egg albumin 
(45 kDa), and cytochrome c (12 kDa) (Serva, Heidelberg, 
Germany). 
3. Results 
3.1. Single amino acid substitutions 
The baculovirus expression products in Sf9 cells were 
purified as 46-kDa single bands on SDS-polyacrylamide 
gel electrophoresis for all five mutants (data not shown). 
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Fig. 1. Alignment of amino acid sequence for human a-Gal and ct-NAGA. The regions for construction of chimeric mutants CMB12 and CMB6, and 
those for single amino acid substitutions are indicated by arrows. Mutations detected in a Fabry disease variant are indicated by open triangles. Vertical 
lines represent identical amino acid residues between a-Gal and a-NAGA. 
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Table 1 
Kinetic properties of mutant enzymes 
Km * Vmax ** Vmax/Km 
(mM) ( /zmol /min per mg) 
W277L 2.4 69.2 28.8 
N278E 2.2 66.7 30.3 
Q280S 5.3 48.6 9.2 
V281R 3.0 65.2 21.7 
T282A 5.0 45.1 9.0 
Normal 2.2 46.8 21.3 
* Substrate: 4MU-a-Gal. Concentrations: 1-8 mM. * * Enzyme activity 
was assayed in 0.1 M sodium citrate buffer (pH 4.6). Each value is the 
mean of three separate determinations. 
Kinetic properties are summarized in Table 1. K m 
increased more than 2-fold for Q280S and T282A. The 
catalytic efficiency expressed as Vm,x/K m toward 4MU-a- 
Gal was decreased only in these two mutants. 
Significant difference was not observed in the CD 
spectrum between the mutants (Q280S, T282A) and nor- 
mal a-Gal (Fig. 2). Superose 12 column chromatography 
suggested that they were monomeric in solution (data not 
shown). 
3.2. Combined mutants 
The chimeric substitution i  CMB12 did not affect the 
stability of enzyme activity (Fig. 3). Single amino acid 
substitutions in Q280S and T282A resulted in a marked 
decrease in thermostability. An additional chimeric substi- 
tution restored the thermostability at acidic pH, but showed 
different effects at neutral pH: decrease in Q280S, and no 
effect in T282A. 
Both Q280S and T282A mutations howed a reduced 
enzyme activity at acidic pH, which was restored to the 
normal evel by the chimeric substitution CMB12 in both 
CMB12-Q280S and CMB12-T282A (Fig. 4), although the 
chimeric mutation CMB12 itself resulted in a decrease of 
catalytic activity [16]. All mutants, except T282A, were 
stable under the assay condition in this study: 37 ° C for 6 
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Fig. 3. Thermostability of mutant enzymes. Purified enzyme (10/~g/ml)  
was incubated at 37 ° C for 30 min in 100 mM citrate-phosphate buffer, 
containing 0.1% Triton X-100, at indicated pH. a-Gal activity was 
assayed after dilution with an excess amount of 0.2 M sodium citrate 
buffer (pH 4.6). The enzyme activity before incubation at each pH was 
defined as 100%. A, a-Gal (©) and CMB12 (0) ;  B, Q280S (O) and 
CMB12-Q280S (0) ;  and C, T282A (O)  and CMB12-T282A (0) .  
min at pH 4.0. The stability of the T282A activity was 
slightly affected at acidic pH. 
K m was 2-fold high in the CMB12 mutant, and an 
additional single amino acid substitution did not affect the 
value in the CMB12-Q280S mutant. However, it increased 
further up to the 3.5-fold higher level in the CMB12-T282A 
mutant (Fig. 5). The combined mutants also showed an 
increase in Vmax, 2-fold, as compared to that for CMB12. 
As a result, the catalytic efficiency Vmax/K m became 
2-fold high for CMB12-Q280S, as compared with that for 
CMB12, and became similar to that for normal o~-Gal. 
4. Discussion 
The data in our present study clearly demonstrated the 
significance of glutamine-280 and threonine-282 for cat- 
alytic activity and thermostability of c~-Gal. A substitution 
for each amino acid (Q280S and T282A) resulted in 
abnormalities of physicochemical and kinetic properties to 
the same degree as CMB6. Three other amino acid substi- 
tutions (W277L, N278E, and V281R) did not affect the 
enzyme activity. 
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Fig. 2. CD spectrum of normal and mutant a-Gal. The proteins were 
analyzed in 10 mM sodium acetate buffer (pH 5.0). 
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Fig. 4. pH-activity curve of  mutant enzyme. Enzyme activity was deter- 
mined with 5 mM 4MU-a-Ga] as substrate in 0.1 M sodium citrate buffer 
at 37 ° C for 6 min, at indicated pH. A, a-Gal (O)  and CMBI2 (0 ) ;  B, 
Q280S (©) and CMB12-Q280S (0) ;  C, T282A (O)  and CMB12-T282A 
(O). 
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Fig. 5. Effects of additional chimeric mutation CMB12 on kinetic proper- 
ties of mutant enzymes Q280S and T282A. For K m determinations, the 
4MU-a-Gal concentration was varied between 1 and 8 mM. Enzyme 
activity was assayed in 0.1 M sodium citrate buffer at indicated pH. 
A,D,G, ot-Gal (C)) and CMB12 (0); B,E,H, Q280S (O) and CMB12- 
Q280S (0); C,F,I, T28ZA (O) and CMB12-T282A (0). 
The catalytic activity may have been slightly affected at 
low pH below 4.5 in T282A due to a decreased thermosta- 
bility under the acidic condition. This effect was less 
prominent under the experimental conditions at pH 4.6 in 
this in vitro study. CD spectrum for these two mutant 
proteins indicated that there was no drastic conformational 
change in the molecule. We assume that glutamine-280 
and threonine-282 are located in or near the active site of 
the enzyme a-Gal. 
The tertiary structure of either a-Gal or a-NAGA is not 
known, but we suggested in a previous tudy [16] that at 
least wo peptide regions #43-87 and #259-286 in a-Gal, 
and probably #29-73 and #245-272 in a-NAGA, com- 
prised the recognition site of a-linked galactose in a 
synthetic substrate 4MU-a-Gal. The chimeric mutant 
CMB126 showed a low affinity to a-linked galactose, at 
the same level as a-NAGA. This low affinity can be 
explained by a replacement of threonine with alanine at the 
amino acid residue 282 in a-Gal, and 268 in a-NAGA, 
based on our observation that CMB12-T282A had a 
markedly high g m with more stability than T282A. 
A stable intramolecular interaction was suggested be- 
tween chimeric mutant CMB12 region and amino acid 
substitution regions (Q280S and T282A) in this study, as 
shown for the interaction between two chimeric regions 
[16]. Vma ~ and thermostability increased in Q280S and 
T282A after addition of the CMB12 mutation, which 
contained 17 amino acid substitutions. The site for this 
stabilization has not been identified at present. 
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